Treatment
Momelotinib clinical trials
We’re tracking 8 recruiting studies that include Momelotinib, each written for real people, not researchers, below.
Recruiting studies
- NCT06517875RecruitingPhase 2
Testing momelotinib plus luspatercept for transfusion-dependent myelofibrosis
This study tests a combination of two drugs, momelotinib and luspatercept, for people with myelofibrosis who need regular red blood cell transfusions. The goal is to see if the combination can reduce transfusion needs and improve symptoms.
Ann Arbor, MichiganAges 18 years+ - NCT06847867RecruitingPhase 2
Testing momelotinib for low-risk myelodysplastic syndrome
This study tests a new drug, momelotinib, for people with a low-risk form of myelodysplastic syndrome (MDS) who need red blood cell transfusions and have already tried one other treatment (like ESAs or luspatercept). The goal is to see if momelotinib can help reduce transfusion needs.
Goodyear, ArizonaAges 18 years+ - NCT07071155RecruitingEarly Phase 1
Momelotinib with a hypomethylating agent for certain blood cancers
This trial tests a combination of two drugs, momelotinib and a hypomethylating agent, for people with certain slow-growing blood cancers. If you have a diagnosis like chronic myelomonocytic leukemia or chronic neutrophilic leukemia and have an enlarged spleen, this study might be exploring a new treatment option for you.
Baltimore, MarylandAges 18–100 - NCT07098936RecruitingPhase 2
Momelotinib for VEXAS syndrome
This trial tests a drug called momelotinib for people with VEXAS syndrome, a rare inflammatory condition. The goal is to see if momelotinib can reduce symptoms and the need for steroids.
AngersAges 18 years+ - NCT07104799RecruitingPhase 1
Momelotinib before and after stem cell transplant for myelofibrosis
This trial tests whether the drug momelotinib, given before and after a stem cell transplant (also called a bone marrow transplant), can help people with myelofibrosis. The hope is that it will make the transplant safer and more effective.
Boston, MassachusettsAges 18 years+ - NCT04176198RecruitingPhase 1/Phase 2
Oral nuvisertib for myelofibrosis after JAK inhibitor failure
This early-phase study tests whether an oral medicine called nuvisertib (TP-3654) can improve symptoms and disease control in people with myelofibrosis, including those who did not respond well to JAK inhibitors. Some participants may also receive nuvisertib with other JAK-related medicines to see which approach works best.
Birmingham, AlabamaAges 18 years+ - NCT06150157RecruitingPhase 1
Study of JNJ-88549968 for CALR-mutated blood cancers
This study tests an experimental drug called JNJ-88549968 in people with certain blood cancers (essential thrombocythemia or myelofibrosis) that have a CALR gene mutation. It may offer a new treatment option for those who haven't responded well to other therapies.
Duarte, CaliforniaAges 18 years+ - NCT05980806RecruitingPhase 2
Selinexor for myelofibrosis with low platelets (no prior JAK inhibitors)
This trial tests a drug called selinexor (taken by mouth) for people with myelofibrosis who have low to moderate platelet counts and haven't tried JAK inhibitors yet. It aims to shrink the spleen and improve symptoms.
Duarte, CaliforniaAges 18 years+
What Momelotinib is being studied for
Conditions with recruiting Momelotinib studies.
Common questions
- Are there clinical trials studying Momelotinib?
- Yes. Clin2 currently lists 8 recruiting studies that include Momelotinib, drawn from the U.S. registry and rewritten for real people so you can see what each is testing and who it's for.
- How do I know if I qualify for a Momelotinib trial?
- Each study lists its own eligibility criteria — rules about condition, age, and prior treatments. On every Clin2 trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Is Momelotinib an approved treatment?
- A drug being studied in a trial may be investigational (still being tested) or already approved and being studied for a new use. Each study page explains what phase it's in. Clin2 does not provide medical advice — talk with your doctor about whether Momelotinib or a specific trial is right for you.
Related treatments
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. A drug appearing here is being studied in a trial and may be investigational. Talk with your doctor about whether a specific treatment or trial is right for you.